Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Identification of nano-mechanical fingerprints as a biomarker for cancer treatment prognosis

Description du projet

Des biomarqueurs nanomécaniques pour un meilleur traitement personnalisé du cancer

Les tumeurs sont des structures très hétérogènes, avec des variations non seulement entre les types de tumeurs mais aussi entre les tumeurs d’un même type et en fonction de leur évolution. De nombreuses tumeurs solides se rigidifient au fur et à mesure de leur croissance dans les tissus de l’hôte. La rigidification est due à l’augmentation des composants structurels de la tumeur, et les forces mécaniques générées en son sein compriment les vaisseaux sanguins intratumoraux, ce qui diminue l’efficacité de l’administration de médicaments. Des études récentes ont démontré qu’une stratégie d’atténuation des contraintes, utilisant des agents antifibrotiques, favorise le ramollissement de la tumeur et facilite l’administration de médicaments, améliorant de ce fait la thérapie. Le projet CancerFingerPrints, financé par l’UE, utilisera la microscopie à force atomique de pointe pour développer des biomarqueurs nanomécaniques permettant de quantifier les caractéristiques mécaniques des tumeurs.

Objectif

In the fight against cancer, it is well recognized that tumors are highly heterogeneous and they might differ considerably not only between tumors types but also among tumors of the same type or even for the same tumor during progression. As a result, the efficacy of standard cancer chemotherapies varies, and while some patients respond to a particular treatment, other patients do not gain any benefit and in many cases, the condition of the patient deteriorates due to adverse effects. Consequently, crucial in cancer therapy is the prediction of a patient’s response to treatment. Failure of standard therapies has led to the introduction of a new era of personalized, patient-specific treatments, which are based on the identification of biomarkers that characterize the state of a particular tumor. Many solid tumors (e.g. breast cancers and sarcomas) stiffen as they grow in a host’s normal tissue. Stiffening is caused by an increase in the structural components of the tumor. As tumor tissue becomes stiffer, mechanical forces are generated within the tumor, that cause the compression of intratumoral blood vessels, resulting in compromised vessel functionality, which leads to poor drug delivery and therapeutic outcomes. Recently, it has been demonstrated that “stress-alleviation” strategy, which uses anti-fibrotic agents to promote tumor softening, improves uniform delivery of drugs and enhances therapy. Here, we propose the use of state-of-the-art Atomic Force Microscopy-AFM techniques for the development of a NanoMechanical biomarker, which will quantify the mechanical FingerPrints of Cancer. This biomarker will aim to: (i)predict the patient’s response to treatment with chemotherapy and (ii)monitor treatment outcomes, in the case of strategies that target tumor mechanical properties (e.g. stress-alleviation therapy). Furthermore, we propose to develop an AFM-based software product to be used as a commercial tool for the measurement of the NanoMechanical biomarker.

Régime de financement

ERC-POC - Proof of Concept Grant

Institution d’accueil

UNIVERSITY OF CYPRUS
Contribution nette de l'UE
€ 150 000,00
Adresse
AVENUE PANEPISTIMIOU 2109 AGLANTZI
1678 Nicosia
Chypre

Voir sur la carte

Région
Κύπρος Κύπρος Κύπρος
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 150 000,00

Bénéficiaires (1)